Biogen Inc.’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on July 15 with some large hospitals declining to use Aduhelm and health insurers delaying a decision while awaiting coverage terms from Medicare.
A study from the Icahn School of Medicine at Mount Sinai shows how cancer can fool immune cells, which normally repair the body, into actually helping develop the disease.
In a roundup review of scientific studies recently published, a study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland further defined the association between comorbidities and poor outcomes with Covid-19.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes the use of miniature lungs and colons to help test Covid-19 treatments.
According to several studies, the risk of contracting COVID-19 or developing a serious case of the disease may be greater depending on blood type.
In a BioSpace interview, Sorrento Therapeutics executives emphasized the stringent process the company went through in identifying the antibody STI-1499, which demonstrated 100 percent inhibition of SARS-CoV-2 in laboratory tests.
As the world battles the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2, biopharma and biotech companies are approaching the fight with various weapons – repurposed drugs, antivirals, vaccines and clinical antibodies. One of the companies deeply involved in clinical antibody development against COVID-19 is San Diego-based Sorrento Therapeutics.
San Diego-based Sorrento Therapeutics is teaming up with New York City-based Mount Sinai Health System to develop an antibody cocktail called COVI-SHIELD to treat COVID-19.
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.